Equity Profile

RGEN

Repligen Corporation

Health CareLife Sciences Tools & Services$8.2B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well Repligen is managing costs and generating income.

N/A

Revenue Growth

Revenue growth is essential to assess the company's ability to expand its market share and meet increasing demand in the bioprocessing sector.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

RGEN Q2-2026 Earnings Preview

Context

Company Snapshot

Repligen Corporation (RGEN) operates in the health care sector, specifically within the life sciences tools and services industry. The company focuses on providing innovative solutions for bioprocessing, which is crucial for the production of biologic drugs. As the demand for biopharmaceuticals continues to grow, Repligen's role in this space becomes increasingly significant.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+11.14%

Avg Stock Reaction

+4.05%

Last Quarter Recap

In Q1-2026, Repligen reported an EPS of $0.48, exceeding estimates by 25%. The stock reacted positively, gaining over 6% the following day.

Management Promises & Guidance

Focus on expanding product offerings in bioprocessing.
Commitment to improving operational efficiencies.
Plans to enhance customer engagement and support.

Expectations

Wall Street Expectations

Overall, expectations are mixed as Repligen has a strong track record of beating earnings estimates, but there is uncertainty regarding revenue growth.

Bull Case

If Repligen continues its trend of beating EPS estimates, it could signal strong operational performance and market demand, leading to a positive stock reaction.

Bear Case

Conversely, if the company fails to meet revenue expectations or provides weak guidance, it could lead to a decline in investor confidence and a negative stock reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported revenue growth rate for the quarter?

Revenue growth is critical for understanding how well Repligen is capitalizing on the increasing demand for bioprocessing solutions.

Will management provide guidance on future earnings or revenue expectations?

Guidance can significantly influence investor sentiment and expectations for the upcoming quarters.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Repligen's ability to sustain high growth rates due to its innovative product pipeline and market leadership.

Supporting Evidence

Repligen has consistently beaten EPS estimates, indicating strong operational execution.

The options market is pricing a lower move than historical averages, suggesting potential for a surprise.

The company's recent investments in R&D could lead to new product launches that drive future revenue.

Key Risk

If revenue growth exceeds 15%, it could challenge the current cautious consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter centers around Repligen's ability to sustain growth in a competitive bioprocessing market.

Bull Confirmed If

A revenue growth rate of over 15% year-over-year would confirm strong demand and operational efficiency.

Bear Confirmed If

If revenue growth is below 5%, it would raise concerns about market demand and operational challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±4.1%

Historical Avg

±6.4%

Pricing cheap

The options market is pricing in a modest move of around 4.1%, suggesting that traders expect some volatility around the earnings report.

Options are pricing ±4.1% while RGEN has averaged ±6.4% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.6%

30d HV

59.6%

Calls (72K)P/C Ratio: 38.48Puts (1K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options pricing cheap in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Repligen beats expectations and raises guidance, history suggests the stock could rise by around 3.95%, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations but management provides cautious commentary, the stock may experience a muted reaction.

Miss

If the company misses on revenue expectations, history suggests a potential decline of around 4.72%, indicating investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in the bioprocessing segment.
2Details on customer demand trends and market expansion efforts.
3Insights into operational efficiencies and cost management strategies.
4Management's outlook on competitive pressures in the bioprocessing market.
5Any commentary on potential partnerships or collaborations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well Repligen is managing costs and generating income.

N/A

Revenue Growth

Revenue growth is essential to assess the company's ability to expand its market share and meet increasing demand in the bioprocessing sector.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

RGEN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+11.14%

Avg Stock Reaction

+4.05%

Last Quarter Recap

In Q1-2026, Repligen reported an EPS of $0.48, exceeding estimates by 25%. The stock reacted positively, gaining over 6% the following day.

Management Promises & Guidance

Focus on expanding product offerings in bioprocessing.
Commitment to improving operational efficiencies.
Plans to enhance customer engagement and support.

Expectations

Wall Street Expectations

Overall, expectations are mixed as Repligen has a strong track record of beating earnings estimates, but there is uncertainty regarding revenue growth.

Bull Case

If Repligen continues its trend of beating EPS estimates, it could signal strong operational performance and market demand, leading to a positive stock reaction.

Bear Case

Conversely, if the company fails to meet revenue expectations or provides weak guidance, it could lead to a decline in investor confidence and a negative stock reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported revenue growth rate for the quarter?

Revenue growth is critical for understanding how well Repligen is capitalizing on the increasing demand for bioprocessing solutions.

Will management provide guidance on future earnings or revenue expectations?

Guidance can significantly influence investor sentiment and expectations for the upcoming quarters.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Repligen's ability to sustain high growth rates due to its innovative product pipeline and market leadership.

Supporting Evidence

Repligen has consistently beaten EPS estimates, indicating strong operational execution.

The options market is pricing a lower move than historical averages, suggesting potential for a surprise.

The company's recent investments in R&D could lead to new product launches that drive future revenue.

Key Risk

If revenue growth exceeds 15%, it could challenge the current cautious consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter centers around Repligen's ability to sustain growth in a competitive bioprocessing market.

Bull Confirmed If

A revenue growth rate of over 15% year-over-year would confirm strong demand and operational efficiency.

Bear Confirmed If

If revenue growth is below 5%, it would raise concerns about market demand and operational challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±4.1%

Historical Avg

±6.4%

Pricing cheap

The options market is pricing in a modest move of around 4.1%, suggesting that traders expect some volatility around the earnings report.

Options are pricing ±4.1% while RGEN has averaged ±6.4% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.6%

30d HV

59.6%

Calls (72K)P/C Ratio: 38.48Puts (1K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options pricing cheap in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Repligen beats expectations and raises guidance, history suggests the stock could rise by around 3.95%, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations but management provides cautious commentary, the stock may experience a muted reaction.

Miss

If the company misses on revenue expectations, history suggests a potential decline of around 4.72%, indicating investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in the bioprocessing segment.
2Details on customer demand trends and market expansion efforts.
3Insights into operational efficiencies and cost management strategies.
4Management's outlook on competitive pressures in the bioprocessing market.
5Any commentary on potential partnerships or collaborations.